Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis-Reference-Cited by-同舟云学术

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

Published:2020-09-27 Issue:6 Volume:37 Page:1030-1037
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatr Dermatol

Author:

Eichenfield Lawrence F.¹,Yosipovitch Gil²,Stein Gold Linda F.³,Kalabis Mizuho⁴,Zang Chuanbo⁴,Vlahos Bonnie⁴,Sanders Paul⁵,Myers Daniela E.⁴,Bushmakin Andrew G.⁶,Cappelleri Joseph C.⁶,Olivadoti Melissa⁴,Paller Amy S.⁷

Affiliation:

1. Rady Children's Hospital, UC San Diego School of Medicine San Diego California USA

2. Miami Itch Center Miller School of Medicine University of Miami Miami Florida USA

3. Henry Ford Health System Detroit Michigan USA

4. Pfizer Inc Collegeville Pennsylvania USA

5. Pfizer R&D UK Ltd Tadworth UK

6. Pfizer Inc Groton Connecticut USA

7. Northwestern University Feinberg School of Medicine Chicago Illinois USA

Funder

Pfizer

Publisher

Wiley

Subject

Dermatology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.14328

Reference12 articles.

1. Atopic Dermatitis: Global Epidemiology and Risk Factors

2. Atopic Dermatitis in Children

3. Childhood atopic eczema

4. Emotional dysfunction, child-family relationships and childhood atopic dermatitis

5. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical anti-inflammatory treatments for eczema: network meta-analysis;Cochrane Database of Systematic Reviews;2024-08-06

2. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies;American Journal of Clinical Dermatology;2024-05-02

3. Topical Treatments in Atopic Dermatitis: An Expansive Review;Journal of Clinical Medicine;2024-04-10

4. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-02-15

5. Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review;Dermatology Practical & Conceptual;2023-10-31